ArticleBlood2007
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.
Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Trial
- Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial.Communications medicine · 2024Article
- A Nomogram for Predicting the Recurrence of Acute Non-Cardioembolic Ischemic Stroke: A Retrospective Hospital-Based Cohort Analysis.Brain sciences · 2023Article
- Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis.Cellular and molecular bioengineering · 2021Article
- Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate.Cellular and molecular bioengineering · 2020Article
- Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates.Research and practice in thrombosis and haemostasis · 2020Article
- Residues W215, E217 and E192 control the allosteric E*-E equilibrium of thrombin.Scientific reports · 2019Article
- Enhancing the anticoagulant profile of meizothrombin.Biomolecular concepts · 2018Article
- Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.Metabolic brain disease · 2015Article
- WEDGE: an anticoagulant thrombin mutant produced by autoactivation.Journal of thrombosis and haemostasis : JTH · 2015Article
- Article
- Role of coagulation in the recruitment of colon adenocarcinoma cells to thrombus under shear.American journal of physiology. Cell physiology · 2013Article
- Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.Arteriosclerosis, thrombosis, and vascular biology · 2013Article
- Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.Biochimica et biophysica acta · 2011Article
- Allostery in trypsin-like proteases suggests new therapeutic strategies.Trends in biotechnology · 2011Review
- Rigidification of the autolysis loop enhances Na(+) binding to thrombin.Biophysical chemistry · 2011Article
- Article
- Article
- Redesigning allosteric activation in an enzyme.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.Science translational medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The anticoagulant and anti-inflammatory enzyme, activated protein C (APC), naturally controls thrombosis without affecting hemostasis. We therefore evaluated whether the integrity of primary hemostasis was preserved during limited pharmacological antithrombotic protein C activator (PCA) treatment in baboons. The double-mutant thrombin (Trp215Ala/Glu217Ala) with less than 1% procoagulant activity was used as a relatively selective PCA and compared with systemic anticoagulation by APC and low-molecular-weight heparin (LMWH) at doses that inhibited fibrin deposition on thrombogenic segments of arteriovenous shunts. As expected, both systemic anticoagulants, APC (0.028 or 0.222 mg/kg for 70 minutes) and LMWH (0.325 to 2.6 mg/kg for 70 minutes), were antithrombotic and prolonged the template bleeding time. In contrast, PCA at doses (0.0021 to 0.0083 mg/kg for 70 minutes) that had antithrombotic effects comparable with LMWH did not demonstrably impair primary hemostasis. PCA bound to platelets and leukocytes, and accumulated in thrombi. APC infusion at higher circulating APC levels was less antithrombotic than PCA infusion at lower circulating APC levels. The observed dissociation of antithrombotic and antihemostatic effects during PCA infusion thus appeared to emulate the physiological regulation of intravascular blood coagulation (thrombosis) by the endogenous protein C system. Our data suggest that limited pharmacological protein C activation might exhibit considerable thrombosis specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.